Muirhead 1989.

Methods	Study design: cross‐over RCT Study duration: NS Duration of follow‐up: NS
Participants	Country: Canada Setting: single centre HD patients; 12 weeks rHuEPO; stable Hb 10.5 to 12.5 g/dL Number: 19 Mean age ± SD (years): NS Sex (M/F): NS Exclusion criteria: NS
Interventions	Treatment group 1 rHuEPO: IV once/wk Received total weekly dose as a weekly injection. Continued for 12 weeks, then crossed‐over Matched placebo: twice/wk Treatment group 2 rHuEPO: IV 3 times/wk for 12 weeks then crossed‐over Dose adjustment was made according to Hb and total weekly rHuEPO dose Co‐interventions NS
Outcomes	Change in Hb Adverse events
Notes	Abstract only Only data for the whole group
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	NS
Allocation concealment (selection bias)	Unclear risk	NS
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Placebo given to weekly rHuEPO group. Patients and staff did not know frequency
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Unclear if outcome assessors blinded but outcome of Hb unlikely to be influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	High risk	31% did not complete the study
Selective reporting (reporting bias)	High risk	Data only available for combined groups
Other bias	Unclear risk	NS